Table 3. Completion of HRQoL questionnaire at each follow-up measurement time according to treatment arm and missing data profile.

		Complete responders			Partial responders
	Arm 1	Arm 2	Total	Arm 1	Arm 2	Total
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
cycle 1	14 (44.1)	15 (50.0)	29 (46.0)	19 (55.9)	15 (50.0)	34 (54.0)
cycle 2	13 (46.4)	7 (35.0)	20 (41.2)	15 (53.6)	13 (65.0)	28 (58.3)
cycle 3	7 (35.0)	1 (10.0)	8 (26.7)	13 (65.0)	9 (90.0)	22 (73.3)
cycle 4	4 (28.6)	1 (50.0)	5 (31.3)	10 (71.4)	1 (50.0)	11 (68.8)
cycle 5	3 (50.0)	1 (50.0)	4 (50.0)	3 (50.0)	1 (50.0)	4 (50.0)
cycle 6	1 (33.3)	0 (0.0)	1 (25.0)	2 (66.7)	1 (100.0)	3 (75.0)
cycle 7	1 (50.0)	0 (0.0)	1 (50.0)	1 (50.0)	0 (0.0)	1 (50.0)
cycle 8	0 (0.0)	0 (0.0)	0 (0.0)	1 (100.0)	0 (0.0)	1 (100.0)
cycle 9	1 (100.0)	0 (0.0)	1 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)
cycle 10	1 (100.0)	0 (0.0)	1 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)

Arm 1: gemcitabine alone; Arm 2: gemcitabine + FOLFIRI.3.